MAB3562
Anti-Sodium/Iodine Symporter Antibody, clone 2-2
clone 2-2, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Na+/I- Symporter, NIS
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
2-2, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... SLC5A5(6528)
Specificity
Sodium/Iodide Symporter (NIS)
Immunogen
Synthetic peptide corresponding to amino acids 37-54 of human NIS.
Application
Anti-Sodium/Iodine Symporter Antibody, clone 2-2 detects level of Sodium/Iodine Symporter & has been published & validated for use in IH & WB.
Immunoblotting. The antibody recognizes a major band at ~97 kDa and minor bands at 15 kDa, 30 kDa, 68 kDa and 160 kDa.
Immunohistochemistry on frozen tissues.
Optimal working dilutions must be determined by end user.
Immunohistochemistry on frozen tissues.
Optimal working dilutions must be determined by end user.
Physical form
Format: Purified
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S Micali et al.
The Journal of endocrinology, 216(2), 125-133 (2012-11-03)
Testicular cancer is the most frequent cancer in young men. The large majority of patients have a good prognosis, but in a small group of tumors, the current treatments are not effective. Radioiodine is routinely used in the treatment of
Elisa Sala et al.
Molecular cancer research : MCR, 6(5), 751-759 (2008-05-07)
BRAF-activating mutations have been reported in several types of cancer, including melanoma ( approximately 70% of cases), thyroid (30-70%), ovarian (15-30%), and colorectal cancer (5-20%). Mutant BRAF has constitutive kinase activity and causes hyperactivation of the mitogen-activated protein kinase pathway.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service